inPractice® - Genotype 1 Patients

AASLD/IDSA guidelines recommend DAA-based regimens for genotype 1 HCV–infected patients according to subgenotype, presence of baseline NS5A resistance associated mutations, and cirrhosis status (Table 24) (Table 25) (Management Guidelines)^{[AASLD-IDSA HCV]}
EASL guidelines also recommend DAA-based regimens for treatment-naive and interferon/ribavirin-experienced patients with genotype 1 HCV infection according to subgenotype and cirrhosis status (Table 26) (Management Guidelines)^{[EASL HCV]}